Beta Drugs Ltd

As of December 1, 2025, Beta Drugs Ltd. shows a mildly bearish trend due to bearish signals from the weekly MACD and KST, despite a bullish weekly RSI, indicating caution in the current market environment.

As of 17-Nov, Beta Drugs Ltd's stock price is 1,654.00, down 0.72%, and has significantly underperformed its sector and the broader market. The stock has seen a substantial drop in trading volume and a year-to-date decline of 13.34%, indicating a lack of investor confidence.

As of November 14, 2025, Beta Drugs Ltd is in a mildly bearish trend, indicated by bearish momentum from the MACD and KST on both weekly and monthly charts, along with bearish signals from Bollinger Bands and On-Balance Volume, despite a mildly bullish daily moving average.

As of November 14, 2025, Beta Drugs Ltd shows a mildly bearish trend, supported by bearish weekly and monthly MACD and KST indicators, despite some mildly bullish daily moving averages.

As of November 14, 2025, Beta Drugs Ltd is in a mildly bearish trend, supported by bearish signals from the weekly MACD, KST, and OBV indicators, despite a mildly bullish daily moving average.

As of November 10, 2025, Beta Drugs Ltd shows a neutral trend with mixed signals, as the weekly MACD is bearish while the RSI is bullish, and moving averages indicate short-term support, but overall indicators suggest a lack of a clear direction.

As of November 7, 2025, Beta Drugs Ltd is in a mildly bearish trend, indicated by bearish MACD and KST signals on weekly and monthly charts, despite a mildly bullish daily moving average, and significant underperformance against the Sensex.

As of November 7, 2025, Beta Drugs Ltd is in a mildly bearish trend, indicated by bearish MACD, KST, and OBV signals, despite some mildly bullish moving averages on the daily chart.

As of November 7, 2025, Beta Drugs Ltd's technical trend has shifted to mildly bearish, influenced by bearish MACD readings, KST and Dow Theory indicators, and negative performance against the Sensex, despite mildly bullish daily moving averages.

Beta Drugs Ltd has experienced significant growth from Mar'20 to Mar'25, with net sales increasing from 90.81 Cr to 362.36 Cr and profit after tax rising from 9.42 Cr to 42.42 Cr, alongside a substantial expansion in total assets and cash flow.

As of 04-Nov, Beta Drugs Ltd's stock price is 1,743.15, down 4.04% and underperforming its sector and the broader market. The stock has seen a significant drop in investor participation and has declined 6.86% over the past week, indicating ongoing struggles.

As of November 3, 2025, Beta Drugs Ltd shows a mildly bullish trend supported by daily moving averages, but caution is advised due to mixed signals from weekly and monthly indicators.

As of 29 October 2025, Beta Drugs Ltd. shows a bullish trend supported by strong daily moving averages and positive signals from Bollinger Bands, KST, and OBV, although caution is advised due to a mildly bearish MACD on weekly and monthly charts.

As of 29-Oct, Beta Drugs Ltd is experiencing a price increase to 1,896.10, with a 1.31% upward change and strong performance indicators, including significant delivery volume growth and positive moving averages. Despite a slight year-to-date decline, the stock shows strong long-term growth potential with a 3-year return of 160.41%.

As of 25-Sep, Beta Drugs Ltd's stock price is 1,800.00, down 1.89%, and has underperformed its sector. Despite a strong long-term performance, recent trends show a decline, with a 5.69% year-to-date drop compared to the Sensex's 5.27% gain.

As of September 23, 2025, Beta Drugs Ltd shows a mildly bullish trend supported by positive MACD and moving averages, though caution is advised due to mixed longer-term indicators.

As of September 10, 2025, Beta Drugs Ltd is in a sideways trend with mixed technical signals, showing bullish weekly indicators but mildly bearish monthly indicators, indicating a lack of clear direction.

As of September 9, 2025, Beta Drugs Ltd is in a mildly bearish trend, indicated by bearish daily moving averages and monthly MACD, despite mixed weekly signals, and has underperformed the Sensex year-to-date.

As of September 1, 2025, Beta Drugs Ltd's technical trend is neutral with mixed signals, showing a mildly bearish daily moving average and conflicting momentum indicators, resulting in a weak overall market direction.